Intravesical treatment with cis-urocanic acid improves bladder function in rat model of acute bladder inflammation

The aim was to study the effect of intravesically instilled cis-urocanic acid (cis-UCA) on bladder function in an experimental rat model of acute bladder inflammation. Hyaluronic acid (HA) was used as a comparator compound.

Bladder irritation was induced in female rats by intravesical hydrochloric acid (HCl) infusion Vehicle, 0 5% HA, or 2% cis-UCA solutions were infused intravesically twice a day for three consequent days On the fourth day, urodynamical measurements were performed, the animals were sacrificed, and the bladders were removed for histopathological assessment

HCl treatment caused significant impairment of bladder function indicated by decreased micturition intervals and voided urine volumes and induced severe voiding dysfunction observed as occurrence of overflow incontinence These functional changes were accompanied by increased bladder weight, hemorrhage, and infiltration of inflammatory cells into the urothelium Intravesical cis-UCA treatment recovered bladder function by significantly prolonging the micturition interval, increasing the voided volume, and reducing the occurrence of overflow incontinence All these changes were comparable to the effects of HA

Intravesical administration of cis-UCA was able to partially recover bladder function impaired by chemical irritation Cis-UCA may offer a novel intravesical treatment option in some inflammatory conditions of the bladder Neurourol Urodynam © 2015 Wiley Periodicals, Inc

Neurourology and urodynamics 2015 Jul 14 [Epub ahead of print]

Yvonne Konkol, Jenni Bernoulli, Tomi Streng, Katarina Jääskeläinen, Jarmo Laihia, Lasse Leino

Pharmatest Services Ltd , Turku, Finland , Pharmatest Services Ltd , Turku, Finland , Department of Biology, Laboratory of Animal Physiology and Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland , BioCis Pharma Ltd , Turku, Finland , BioCis Pharma Ltd , Turku, Finland , BioCis Pharma Ltd , Turku, Finland


Pelvic Health Weekly Newsletter